Rösch Manuel, Bieg Christian, Savic Spasenija, Buess Martin
Department of Medical Oncology, Basel University Hospital, Basel, Switzerland.
Radiology Department, St. Claraspital, Basel, Switzerland.
Case Rep Oncol. 2023 Feb 23;16(1):109-115. doi: 10.1159/000529470. eCollection 2023 Jan-Dec.
Salivary duct carcinoma (SDC) is a rare subtype of salivary cancers associated with androgen receptor and human epidermal growth factor receptor 2 (HER2/neu) overexpression. It shows a high propensity to give rise to distant metastases mainly to the lung, the bone, and the liver. Intracranial metastases are rare. We report the case of a 61-year-old male patient with SDC developing intracranial metastases. Unresponsive to radiotherapy and anti-HER/neu targeted therapy the intracranial metastases showed a very good partial remission to androgen deprivation therapy with goserelin acetate. This case demonstrates the potential of a highly targeted therapy with a relatively cheap and well-known drug in a patient with a rare disease without other good therapeutic options, which is a good example of modern, personalized medicine.
涎腺导管癌(SDC)是涎腺癌的一种罕见亚型,与雄激素受体及人表皮生长因子受体2(HER2/neu)过表达相关。它极易发生远处转移,主要转移至肺、骨和肝脏。颅内转移罕见。我们报告一例61岁男性涎腺导管癌患者发生颅内转移的病例。该患者对放疗及抗HER/neu靶向治疗无反应,而醋酸戈舍瑞林进行雄激素剥夺治疗后,颅内转移灶出现了非常好的部分缓解。本病例显示,对于一种罕见病且没有其他良好治疗选择的患者,使用一种相对便宜且知名的药物进行高度靶向治疗具有潜力,这是现代个性化医疗的一个良好范例。